Uniqure announces positive interim data update demonstrating slowing of disease progression in phase i/ii trials of amt-130 for huntington's disease

~ achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; patients receiving high-dose amt-130 showed 80% slowing of disease progression in the composite unified huntington's disease rating scale (cuhdrs) at 24 months compared to a propensity score-weighted external control ~
AMT Ratings Summary
AMT Quant Ranking